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Assessment of biological exposure is a key
challenge in evaluating metal toxicity, for
both clinicians and epidemiologists. Blood
and urine measurements traditionally have
been used, but these have several shortcom-
ings, such as failure to reﬂect true body bur-
den, failure to correlate with biological
effects, high interperson variability following
similar exposures, and relatively rapid clear-
ance (1). X-ray fluorescence is being used
increasingly to assess exposure to lead but not
to other metals (2–5).
Because chelating agents bind metals
and promote their urinary excretion, theo-
retically they can be used in challenge tests
to assess metal levels. The rationale for
diagnostic chelation challenge is straightfor-
ward: If a person has an elevated body bur-
den of a metal, then administration of a
chelating agent should cause a short-term
increase in the urinary excretion of that
metal. The most commonly used chelation
challenge test has been EDTA administra-
tion following lead exposure (6,7),
although British Anti-Lewisite and penicil-
lamine have also been used (8). More
recently, attention has focused on dimer-
captosuccinic acid (DMSA), or succimer, a
chelating agent approved by the U.S. Food
and Drug Administration (U.S. FDA) in
1991 for the treatment of pediatric lead
toxicity.
DMSA is used primarily in the treatment
of metal toxicity, rather than in diagnosis.
The most common therapeutic use has been
in treating lead toxicity (9–11), but DMSA
has also been used to treat a variety of other
metal overexposures (12–14). Besides its
treatment role, DMSA offers considerable
diagnostic potential as a chelation challenge
agent. First, it is convenient: DMSA is an
oral agent, whereas EDTA must be adminis-
tered parenterally. Second, DMSA has an
excellent safety profile. Third, DMSA has
been shown to mobilize a range of metals
effectively in both animals and humans.
Fourth, DMSA acts quickly. The blood con-
centration of DMSA peaks in 3 hr, and the
half-life is 3.2 hr (15). DMSA-induced excre-
tion of both lead (16) and mercury (17)
peaks within 2 hr. In the clinical setting,
chelation challenge would therefore require
urinary collection only over several hours.
For these reasons, DMSA chelation challenge
could be a convenient, safe approach to
assessing the biological burden of various
metals. Indeed, DMSA chelation challenge
has been used in several studies (16,18,19)
and in clinical settings to assess lead burden.
Another metal that might be assessed in
this way is mercury. DMSA mobilizes mer-
cury effectively in both animals (20–25) and
in humans (8,17,26–31). However, unlike
lead, mercury undergoes relatively little
bioaccumulation. It is excreted with a half-life
of 1–2 months (17,32–35). This suggests that
the primary use of DMSA chelation challenge
for mercury would occur in the first weeks
after exposure. However, a long terminal
elimination phase has been described (36),
with mercury retention in nervous system,
kidneys, and other soft tissues. Consequently,
there could also be a role for DMSA chelation
challenge some time after mercury exposure,
especially if exposure had been prolonged and
intense. Support for this notion comes from
animal evidence (37) that DMSA draws mer-
cury with special avidity from the kidneys—
an important mercury storage site known to
have a relatively slow turnover (38). Indeed,
DMSA chelation challenge has been used
clinically on a limited basis following mercury
exposure (15,26,39). A related agent used in
Europe, 2,3-dimercaptopropane-1-sulfonic
acid (DMPS), has been used in a similar
manner (40,41).
At present the interpretation of DMSA
challenge tests for mercury is difficult
because we lack reliable data on the normal
range of mercury excretion in unexposed
people following DMSA, the expected range
of elevations following mercury exposure,
the correlation between DMSA response and
other measures of mercury exposure, and the
clinical signiﬁcance of elevations. Such data
would be necessary to validate the DMSA
chelation challenge response as a practical,
informative biomarker of mercury exposure.
In this paper we report a study of DMSA
chelation challenge testing among workers
with long-term, high-level exposure to mer-
cury in a chloralkali plant and among a com-
parison population of unexposed workers.
Methods
Study subjects. This study was conducted as
part of a larger study of the health effects of
Address correspondence to H. Frumkin, Department
of Environmental and Occupational Health, Rollins
School of Public Health, Emory University, 1518
Clifton Road, Atlanta, GA 30322 USA. Telephone:
(404) 727-3697. Fax (404) 727-8744. E-mail:
medhf@sph.emory.edu
This study was funded by grant 1 RO1 ES08346
from the National Institute of Environmental
Health Sciences.
Received 7 July 2000; accepted 28 September
2000.
Articles
Chelation challenge testing has been used to assess the body burden of various metals. The best-
known example is EDTA challenge in lead-exposed individuals. This study assessed diagnostic
chelation challenge with dimercaptosuccinic acid (DMSA) as a measure of mercury body burden
among mercury-exposed workers. Former employees at a chloralkali plant, for whom detailed
exposure histories were available (n = 119), and unexposed controls (n = 101) completed 24-hr
urine collections before and after the administration of two doses of DMSA, 10 mg/kg. The uri-
nary response to DMSA was measured as both the absolute change and the relative change in
mercury excretion. The average 24-hr mercury excretion was 4.3 µg/24 hr before chelation, and
7.8 µg/24 hr after chelation. There was no association between past occupational mercury expo-
sure and the urinary excretion of mercury either before or after DMSA administration. There was
also no association between urinary mercury excretion and the number of dental amalgam sur-
faces, in contrast to recent published results. We believe the most likely reason that DMSA chela-
tion challenge failed to reﬂect past mercury exposure was the elapsed time (several years) since the
exposure had ended. These results provide normative values for urinary mercury excretion both
before and after DMSA challenge, and suggest that DMSA chelation challenge is not useful as a
biomarker of past mercury exposure. Key words: biomarkers, chelation, chloralkali, DMSA, envi-
ronmental diseases, mercury, neurotoxicity, occupational diseases, renal toxicity, succimer.
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chloralkali plant in Brunswick, Georgia (42).
The plant had operated from 1956 to 1994.
We identified 221 former employees who
had worked in the plant for at least a year,
who were still alive at the time of the study
in 1998, and who could be contacted. We
also identiﬁed a large pool of unexposed per-
sons who worked for three local employers: a
local government, a quasi-governmental
tourist authority, and a paper company.
Individuals from this pool were selected
according to a scheme that matched their
age-race-sex distribution to that of the
exposed subjects, and were invited to partici-
pate in the study. Participation consisted of
completing a detailed questionnaire, physical
examination, neurological and neurobehav-
ioral testing, and blood and urine testing, in
addition to the portions of the study speciﬁ-
cally related to the chelation challenge.
These elements of the study are reported in
detail in the companion paper (42). Of note,
the questionnaire and physical examination
were designed to assess several sources of
exposure to mercury. The questionnaire
asked about other occupational sources of
mercury exposure and about dietary sources,
including fish. The physical examination
included a count of the number of tooth sur-
faces with mercury amalgam ﬁllings. 
We performed an extensive exposure
assessment as part of the larger study. Using
personnel records, we recorded each former
employee’s job history within the plant. We
also identiﬁed the air mercury exposure lev-
els at each part of the plant, for each job
title, for each year of the plant’s operation.
These estimates, generated from historical
air sampling data, were validated by compar-
ison with available urinary mercury sampling
and with modeled air levels based on mer-
cury throughput data and room air change
parameters (43). We then created a job-
exposure-year matrix and reconstructed an
exposure profile for each former employee.
We used three metrics of exposure: average
exposure (in micrograms per cubic meter),
cumulative exposure (in micrograms per
cubic meter per year), and peak exposure (in
micrograms per cubic meter). Mercury expo-
sure had been high in the cell room and in
other parts of the plant, with air levels aver-
aging above 100 µg/m3 for some employees
(43), comparable to the exposures reported
from contemporary chloralkali plants
(44–46). 
Sample collection and analysis. Each
subject collected a baseline 24-hr urine sam-
ple. Approximately 2 weeks later the subjects
returned for a second test session. At that
time we administered two doses of DMSA,
10 mg/kg, at 8-hr intervals. Each subject
commenced a second 24-hr urine collection
at the time of the ﬁrst dose. Both urine col-
lections, the baseline and the post-DMSA,
used plastic containers provided by the
Centers for Disease Control and Prevention
(CDC; Atlanta, GA); all lots were tested to
conﬁrm that they were metal-free. 
Both the baseline and the post-DMSA
urine samples were kept refrigerated during
the collection and were returned on the day
the collection was completed (or, in rare
cases, on the following day). We measured
the volume of each 24-hr collection and
then decanted approximately 50 mL into
metal-free plastic specimen containers for
transfer to the laboratory. The specimens
were kept refrigerated throughout. If a 24-hr
urine collection had a volume < 500 mL or a
total creatinine < 700 mg it was considered
incomplete and was excluded.
On each sample we measured the creati-
nine and the mercury levels. All measure-
ments were performed at the laboratories of
the CDC National Center for Environmental
Health in Atlanta. We measured mercury in
undigested urine by cold vapor atomic
absorption analysis based on the method of
Littlejohn et al. (47) using modiﬁed reagents
as described by Greenwood et al. (48).
Standard quality-assurance procedures,
including replicate testing and the use of
blanks and standards, were followed. Urinary
mercury concentration was standardized to
creatinine concentration and expressed in
units of milligrams per gram creatinine.
Data analysis. We considered three met-
rics of urinary mercury response to DMSA:
the absolute amount of mercury excreted in
response to DMSA (in micrograms per 24
hr), the change in mercury excreted follow-
ing DMSA (postchelation mercury excretion
minus baseline mercury excretion, in micro-
grams per 24 hr, henceforth referred to as
difference), and the ratio of the mercury out-
put in the second collection to the mercury
output in the first collection, henceforth
referred to as the ratio. 
We characterized the distribution of each
variable among the exposed and the unex-
posed, and the entire study group. We then
undertook four analyses to assess the associa-
tion between mercury exposure and chela-
tion response.
First, we examined the correlation of
exposure ranks and chelation challenge
response ranks. We reasoned that if expo-
sure were associated with chelation chal-
lenge response, the subjects exposed most
heavily would have some of the highest
chelation challenge response ranks and, sim-
ilarly, that those with the most active
response to chelation challenge would have
some of the highest exposure ranks. We
therefore identified the 15 most heavily
exposed former workers, according to each
of the three exposure metrics we used (aver-
age, cumulative, and peak exposure), arrayed
them according to their exposure ranks, and
observed their chelation challenge response
ranks. Conversely, we identiﬁed the 15 most
active responders to chelation challenge, in
terms of both difference and ratio, arrayed
them according to their chelation challenge
response ranks, and observed their exposure
ranks. 
Second, in a more formal assessment of
this correlation, we calculated the Spearman
rank–order correlation coefficients for the
association between exposure and chelation
challenge response, using ranks. We selected
this nonparametric test because not all vari-
ables were normally distributed. We repeated
this analysis for three metrics of exposure—
cumulative, mean, and peak—and for two
metrics of chelation challenge response—dif-
ference and ratio—producing six correlation
coefﬁcients. 
Third, in an extension of this approach,
we carried out multiple linear regression, with
occupational mercury exposure and number
of dental amalgam surfaces as independent
variables, and chelation challenge response as
the dependent variable. In this analysis, the
occupational mercury exposure was set at zero
for all unexposed subjects. To satisfy the lin-
ear regression assumption that the residuals
follow a normal distribution, both metrics of
chelation challenge response—difference and
ratio—were transformed. Van der Waerden’s
transformation into the normalized rank was
applied to the difference, and the ratio was
transformed using the natural logarithm. This
regression was run on the combined group of
exposed and unexposed subjects, and on the
exposed and unexposed subsets separately.
Finally, because a possible association
might be apparent only in subjects with
relatively recent exposure, we repeated all
analyses, restricting them to those former
employees whose employment had lasted
into the ﬁve years before our testing. 
Results
Of the 221 eligible former employees of the
chloralkali plant, 156 participated com-
pletely or partly in the study. There were
nine subjects with diabetes, one with renal
failure, and 27 who did not provide two
usable 24-hr urine collections or who had
missing data, leaving 119 exposed subjects.
Of the 190 unexposed subjects invited to
participate based on the age-race-sex distrib-
ution of the former employees, 138 partici-
pated. There were two unexposed subjects
with diabetes, and 35 who did not provide
two usable 24-hr urine collections or who
had missing data, leaving 101 unexposed
subjects. The results are based on data from
these two groups. 
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the chelation study had an exposure profile
virtually identical to that of the larger popu-
lation of exposed workers, as reported else-
where (42). The mean duration of exposure
was 7.0 years, and the mean time since last
exposure was 6.1 years. The mean workplace
mercury exposure level was 33.8 µg/m3, the
mean of the peak exposure levels was 71.9
µg/m3, and the mean cumulative exposure
was 236.8 µg/m3–years. 
Table 1 shows data on urinary mercury
for the exposed and unexposed groups.
Although the exposed workers tend to have
greater mercury excretion than the unex-
posed workers, the differences do not reach
statistical significance. Among the exposed
workers, only one subject had a relatively
high postchelation urinary mercury output;
otherwise the distributions of the exposed
and unexposed subjects were nearly identical.
Tables 2 and 3 show the results of the
rank correlation analysis. These tables show
data only for the exposed subjects, each of
whom was ranked on several metrics of
exposure and on the urinary mercury
response to chelation. Table 2 shows the 15
highest-ranking subjects in terms of exposure
(expressed in three ways: cumulative, mean,
and peak exposure), with their respective
ranks on chelation challenge response
(expressed in two ways: as post/pre-chelation
absolute difference and as the post:pre ratio).
Table 3 shows the reverse: the 15 highest-
ranking postchelation mercury excreters
(expressed in two ways), with their respective
exposure ranks (expressed in three ways).
Because there are three exposure metrics and
two metrics of chelation challenge response,
each panel of the table shows six compar-
isons. In each case, visual inspection reveals
that many of the highest-scoring subjects for
one parameter had low scores on the other
parameter. 
The analysis whose results appear in
Tables 2 and 3 was limited to exposed sub-
jects, since only they were eligible to be
ranked on both exposure and chelation chal-
lenge response. However, we also con-
structed an alternative version of Table 3
that included unexposed subjects (data not
shown). Of the top-scoring subjects in terms
of chelation challenge response, eight (using
the difference score) or nine (using the ratio
score) were unexposed. Thus, more than half
of the most active responders to chelation
challenge had no history of occupational
mercury exposure. 
Table 4 shows the Spearman rank-order
correlation coefficients for the associations
between exposure and chelation challenge
response. Two of the results—for the differ-
ence scores correlated with average and peak
exposure—reached marginal statistical 
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Table 1. Mercury excretion before and after DMSA chelation.
Exposed Unexposed p-Value
Values (n = 119) (n = 101) for difference
Baseline values
Urinary Hg concentration, uncorrected (µg Hg/L)
Group mean ± SD 3.37 ± 2.51 2.89 ± 2.18 0.13
95% value 9.0 6.5
Maximum value 18.2 12.8
Urinary Hg concentration, corrected 
(µg Hg/g creatinine)
Group mean ± SD 2.74 ± 2.05 2.26 ± 1.92 0.08
95% value 7.00 5.62
Maximum value 11.75 11.82
24-hr Hg excretion (µg/24 hr)
Group mean ± SD 4.61 ± 3.85 3.94 ± 3.43 0.17
Maximum value 21.84 22.4
Postchelation values
24-hr Hg excretion (µg/24 hr)
Group mean ± SD 7.87 ± 5.85 7.73 ± 5.58 0.87
Maximum value 46.81 27.94
Change in 24-hr Hg excretion
(post-DMSA–baseline, µg/24 hr)
Group mean ± SD 3.25 ± 5.96 3.80 ± 5.53 0.48
Range –14.59, 39.66 –10.70, 25.39
Ratio of post-DMSA Hg excretion to 
baseline mercury excretiona
Group mean ± SD 2.40 ± 2.25 2.77 ± 2.58 0.27
Range 0.23, 16.66 0.26, 18.29
aExcludes one unexposed subject whose baseline Hg excretion was 0.
Table 2. Association of exposure ranks and chelation challenge response ranks among the most heavily
exposed subjects.
Exposure  Cumulative exposure  Mean exposure  Peak exposure 
rank Difference Ratio Difference Ratio Difference Ratio
11 2 1 1 1 6 8 0 8 6
2 15 8 56 49 4 3
38 0 8 6 7 1 6 4 1 5 8
4 36 15 109 114 74 81
57 4 8 1 8 8 5 9 2 2 4 3
61 9 3 3 2 3 2 9 1 9 3 3
79 6 9 1 1 4 1 9 1 2 1 1
81 6 3 7 6 9 8 5 9 6 9 1
97 0 7 4 3 5 3 4 3 8 5 7
10 111 108 39 70 73 83
11 5 16 103 100 69 85
12 54 7 31 39 20 4
13 4 3 19 33 14 19
14 81 89 38 57 39 70
15 75 56 93 96 28 25
n = 119; ranks can range between 1 and 119.
Table 3. Association of exposure ranks and chelation challenge response ranks among subjects with the
highest chelation challenge ranks.
Chelation Difference Ratio
challenge rank Cumulative Mean Peak Cumulative Mean Peak
1 99 1.0 26.0 59 88.0 71.5
2 59 88.0 71.5 48 101.0 103.0
3 32 87.0 78.5 13 27.0 4.5
4 13 27.0 4.5 66 30.0 11.5
5 11 55.0 18.5 69 38.0 53.5
6 94 66.0 103.0 99 1.0 26.0
7 100 89.5 94.0 12 20.5 18.5
8 48 101.0 103.0 2 49.0 4.5
9 69 38.0 53.5 100 89.5 94.0
10 73 108.0 97.0 31 36.0 46.5
11 27 93.0 93.0 1 24.0 4.5
12 1 24.0 4.5 19 58.0 51.0
13 74 48.0 86.0 104 40.0 63.5
14 29 7.0 11.5 94 66.0 103.0
15 2 49.0 4.5 4 47.0 46.5
n = 119; ranks can range between 1 and 119.signiﬁcance (p = 0.05 and 0.04, respectively).
However, multiple comparisons were made,
and a Bonferroni correction procedure
would reduce the statistical significance of
these two results. 
The multiple linear regression analysis,
including both exposure scores and dental
amalgam surfaces as independent variables,
showed no significant associations between
any measure of exposure and chelation chal-
lenge response (Table 5). There was a signiﬁ-
cant association between the number of
dental amalgam surfaces and the chelation
challenge when the two groups, exposed and
unexposed, were analyzed together. However,
this association went in the unexpected direc-
tion: More amalgam surfaces were associated
with a lower post/pre ratio. When exposed
and unexposed subjects were analyzed sepa-
rately, the number of amalgam surfaces was
not signiﬁcantly associated with the chelation
challenge response (data not shown).
Finally, when we repeated the analyses
including only the 88 former workers who
had been employed within the 5 years before
the study, we found no significant associa-
tions between any measure of occupational
mercury exposure and any measure of chela-
tion challenge response. In particular, the
two borderline statistically significant find-
ings shown in Table 2 became nonsignifi-
cant (p = 0.61 and 0.42, respectively). In
addition, the signiﬁcant (if unexpected) asso-
ciations shown in Table 5 between dental
amalgam surfaces and chelation challenge
response became nonsigniﬁcant. 
Discussion
Our study hypothesis was that DMSA
chelation challenge might indicate the body
burden of mercury in a population with
chronic occupational mercury exposure,
tested several years after the end of exposure.
The results do not support this hypothesis,
and suggest that DMSA chelation challenge
is not useful in quantifying past mercury
exposure.
Our results do provide useful normative
data on urinary mercury levels, both pre-
and postchelation. Subjects in this study
excreted an average of approximately 4 µg of
mercury in 24 hr before the administration
of DMSA, a quantity that roughly doubled
following two doses of DMSA (Table 1).
These results did not vary with past occupa-
tional exposure status. Given our observed
standard deviations (SDs), and assuming a
normal range that extends to 2 SDs above
the mean, the normal upper limit of 24-hr
urinary mercury excretion would be approxi-
mately 12 µg without chelation treatment,
and 20 µg after two doses of DMSA. We
believe these are the first population data
published on the mercury response to
DMSA chelation challenge.
It is possible that our negative findings
were due to misclassification of past expo-
sures. However, we believe that such error is
unlikely to explain our results; our exposure
assessment was based on a large body of
direct measurements, veriﬁed by internal val-
idation procedures, and consistent with
other studies of mercury levels in chloralkali
plants (43). Moreover, exposure misclassiﬁ-
cation would not account for the fact that
our exposed and unexposed subjects had
similar proﬁles of urinary mercury excretion. 
It is also possible that our urinary collec-
tion procedure—speciﬁcally, collecting urine
for 24 hr rather than a shorter interval—
accounted for the negative findings. Other
studies have collected urine for shorter inter-
vals, in the range of 8 hr, based on the rapid
action of DMSA in effecting mercury excre-
tion [e.g., Aposhian et al. (49)]. A longer
collection may have diluted our results by
diluting the mercury in our specimens, caus-
ing the results for the highly exposed and the
unexposed to converge. However, given the
uniformly low levels of urinary mercury
among both exposed and unexposed individ-
uals, we believe it is unlikely that a shorter
collection period would have altered our
ﬁndings substantially. 
We believe that the most likely cause of
the inability of DMSA chelation challenge to
quantify past mercury exposures was the
elapsed time between the exposures and the
testing. As discussed above, most mercury is
cleared within 1–2 months, apparently to
levels too low to be assayed by DMSA chal-
lenge. Other approaches to retrospective
exposure assessment will be required in
future studies of mercury epidemiology.
We also found that the response to
DMSA chelation challenge did not increase
with the number of mercury amalgam ﬁlling
surfaces. Prior evidence suggests that dental
amalgam ﬁllings do cause systemic mercury
absorption (50–52). In addition, at least two
studies have reported an association between
dental amalgam fillings and mercury excre-
tion following chelation with either DMPS
(49) or DMSA (29). The negative ﬁnding in
our study may indicate that dental amalgam
fillings do not create enough systemic mer-
cury absorption to be detected by DMSA
chelation with the protocol we used. It is
also possible that our assessment of dental
amalgam (counting surfaces rather than
measuring surface area) or our challenge pro-
tocol (the DMSA dose we used and/or the
timing of our collection) limited our ability
to detect a true association. 
We attempted to validate a potential
biomarker of long-term occupational mer-
cury exposure, the DMSA chelation chal-
lenge response, by studying the association
of this biomarker with quantitative esti-
mates of exposure in a cohort of exposed
and unexposed individuals. The biomarker
could not distinguish exposed and unex-
posed subjects, and it was not associated
with the magnitude of exposure. We con-
clude that DMSA chelation challenge,
according the protocol described here, is not
useful in retrospective exposure assessment
among mercury workers. 
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